About brentuximab vedotin
CD30-directed antibody-drug conjugate
Used for
- Treats certain Hodgkin lymphomas and anaplastic large cell lymphomas.
- Used alone or with other cancer medicines, depending on the lymphoma and treatment setting.
Usual adult dose
Usually 1.2 mg/kg or 1.8 mg/kg by intravenous infusion every three weeks, depending on the condition and regimen; maximum 180 mg per dose.
Usual dose in children
For eligible patients aged 2 years and older, usually 1.8 mg/kg by intravenous infusion every three weeks; maximum 180 mg per dose.
Common side effects
- Numbness, tingling, or weakness from nerve damage
- Low blood cell counts and increased infection risk
- Nausea, diarrhoea, tiredness, or fever
- Infusion reactions or rash
Important warnings
- Can cause serious nerve damage, severe infections, and low blood counts.
- Rarely causes progressive multifocal leukoencephalopathy, a serious brain infection.
- May cause severe skin reactions, pancreatitis, or liver injury.
- Infusion requires monitoring; doses may need adjustment for side effects or liver problems.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for six months after the final dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for six months after the final dose.
Interactions
- Bleomycin: combination is contraindicated because of severe lung toxicity risk.
- Strong CYP3A4 inhibitors, such as ketoconazole, may increase exposure and side effects.
- Strong CYP3A4 inducers, such as rifampin, may reduce exposure.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.